Registry participants with advanced malignancy or myelodysplasia will have a sample of their
tumor or tissue analysed for genetic alterations using next generation sequencing (NGS)
performed in a lab that has been certified to meet a high quality standard. Treatments and
outcomes will be reported to the registry to allow further understanding of how genetic
differences can lead to better diagnosis and treatments.